BUY Zydus Lifesciences Limited — Rajesh Palviya, Axis Securities
byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))29 Sept 2026via ET Now (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
MACD above its signal line — bullish momentum
Technicals · macd·29 Sept · today
The USFDA concluded a cGMP inspection at the company's SEZ II manufacturing plant in Ahmedabad with only one observation and no data integrity issues.
BSE · Company Update·28 Sept · today
5 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·29 Sept · today
Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations
NewsCnbc-Tv18·26 Sept · 3d ago
The USFDA inspection of Zydus Lifesciences' USA office for pharmacovigilance and post-marketing systems concluded with no observations.
BSE · Company Update·26 Sept · 3d ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.